Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Bio-NeuroScience 2026
39 slides from Alzecure Pharma Ab's conference presentation, Feb 24, 2026
Slide 1: Developing therapies for Alzheimer's & pain
Bio-NeuroScience 2026 FEBUARY 24, 2026 Developing therapies for Alzheimer’s & pain
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements regarding the Company’s intentions, assessments, or expectations in respect of the Company’s future results, financial position, liquidity, development, prospects, expected growth, strategies and possibilities as well as the market wit
Slide 3: AlzeCure Pharma in brief
AlzeCure Pharma in brief
Slide 4: AlzeCure Pharma – In brief
Introduction AlzeCure Pharma – In brief • Working in Alzheimer’s Disease (AD) & Pain – high unmet medical need & multi-billion sales Professor Jan Lundberg – Board member Former global head of R&D at Eli Lilly & global head potential of research at AstraZeneca joining & investing • Spin-out from Ast
Slide 5: Our Business Model
Introduction Our Business Model Are a Research & Development company Research & develop through early clinical phase and then to out-license or partner on our projects Gain incomes through: Upfront Milestone Royalties on payments payments sold products 5
Slide 6: A pipeline of Small-Molecule Programs
Introduction A pipeline of Small-Molecule Programs Multiple candidates increase chance of success Research Preclinical Phase I Phase II Phase III Platform Candidate Target Indication phase phase Alzheimer’s Disease, Positive allosteric TBI - Traumatic brain Positive read-out Neuro ACD856 modulator (
Slide 7: Two Alzheimer's platforms - 1st-in-class properties & potential game-changers
Two Alzheimer’s platforms - 1st-in-class properties & potential game-changers MEETING NEEDS OF AD PATIENTS – ADRESSING SHORT TERM NEEDS WITH LONG-TERM BENEFITS Preventive Disease-modifying therapy Symptomatic & pot. Disease-modifying therapy Alzstatin® NeuroRestore® Gamma-secretase modulator Trk-PAM
Slide 8: NeuroRestore – Trk-PAM improving neuronal function & cognition in Alzheimer's disease
NeuroRestore® – Trk-PAM improving neuronal function & cognition in Alzheimer’s disease
Slide 9: The importance of BDNF & NGF signaling in Alzheimer's
NeuroRestore® – positive allosteric modulator of Trk-receptors The importance of BDNF & NGF signaling in Alzheimer’s • The neurotrophins Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) bind to their respective receptors, TrkB and TrkA and are key for brain health and cognition
Slide 10: Mechanism of Action of NeuroRestore ACD856
NeuroRestore® – positive allosteric modulator of Trk-receptors Mechanism of Action of NeuroRestore ACD856 TrkA/B • ACD856 is a novel oral small molecule positive modulator of Trk-receptors enhancing the signaling of neurotrophins such as NGF & BDNF NGF/ BDNF • The enhanced signaling leads to immedia
Slide 11: NeuroRestore – Cognitive Enhancer Improving Learning & Memory Ability
NeuroRestore® – positive allosteric modulator of Trk-receptors NeuroRestore® – Cognitive Enhancer Improving Learning & Memory Ability Stages of memory formation LEARN STORE REMEMBER Transforming information Maintaining the encoded Re-accessing the information into a form that can be stored in inform
Slide 12: Preclinical data on Pro-cognitive & Disease Modifying Effects
NeuroRestore® – positive allosteric modulator of Trk-receptors Preclinical data on Pro-cognitive & Disease Modifying Effects ACD856 improves aged-induced memory impairment • 18-months old animals were used to study effects on age-induced memory Supporting data impairment and compared to young animal
Slide 13: Phase I Demonstrated Safety, Tolerability & Target Engagement
NeuroRestore® – positive allosteric modulator of Trk-receptors Phase I Demonstrated Safety, Tolerability & Target Engagement • ACD856 is safe & well tolerated − Single and repeated dosing with ACD856 did not result in any serious adverse events in healthy volunteers at the tested dose levels • ACD85
Slide 14: Grant financed Phase IIa study of ACD856 in Alzheimer's disease
NeuroRestore® – positive allosteric modulator of Trk-receptors Grant financed Phase IIa study to investigate the safety & efficacy of ACD856 in Alzheimer’s disease https://www.alzecurepharma.se/en/alzecure-receives-eu-grant-for-phase-2-clinical-trial-of-neurorestore-acd856-for-alzheimers-disease/ 14
Slide 15: TrkA-PAM by Eisai: Disease-Modifying Therapy for Neurodegenerative Diseases
NeuroRestore® – positive allosteric modulator of Trk-receptors TrkA-PAM by Eisai: Disease-Modifying Therapy for Neurodegenerative Diseases ” These results support further development of E2511 as a disease-modifying therapy for neurodegenerative diseases” The data is validating & increasing interest
Slide 16: AlzeCure's ACD856 in Comparison to Eisai's E2511
Other AlzeCure’s ACD856 in Comparison to Eisai’s E2511 Eisai E2511 AlzeCure ACD856 Mechanism of Action Positive allosteric modulator Positive allosteric modulator Target TrkA TrkA, TrkB and TrkC Type Novel small molecule (<400 Da) Novel small molecule (<400 Da) IP Patent granted Patent granted in US
Slide 17: Alzstatin – gamma-secretase modulator targeting amyloid production
Alzstatin® – gamma-secretase modulator targeting amyloid production for prevention and treatment of Alzheimer’s disease
Slide 18: The Alzheimer's Brain and its Destruction by Toxic Protein
Alzstatin ® – gamma-secretase modulator The Alzheimer’s Brain and its Destruction by Toxic Protein The Amyloid Cascade Toxic protein formations, built up of Aβ42, are harming and destroying brain structures AlzeCure’s GSM1 Alzstatin® reduces Aβ42 to diminish the build-up of toxic fragments & plaque
Slide 19: Alzstatin – Potent Reduction of Toxic Aβ42 & Increasing Protective Aβ37 & Aβ38
Alzstatin ® – gamma-secretase modulator Alzstatin® – Potent Reduction of Toxic Aβ42 & Increasing Protective Aβ37 & Aβ38 Alzstatin® potently reduces the amount of Alzstatin® reduces toxic Aβ42 and Aβ40, while toxic brain Aβ42 in animals increasing protective Aβ38 and Aβ37 peptides Αβ42 150 3000 % of
Slide 20: New preclinical data shows Induced Plaque Regression
Alzstatin ® – gamma-secretase modulator New preclinical data shows Induced Plaque Regression Two-photon-study preclinical study in APP/PS1 mice Vehicle AZ4126 Day 0 Day 28 Day 0 Day 28 Distribution of plaque growth & Plaque appearance or regression disappearance 28-day GSM treatment Reduces amyloid
Slide 21: Multiple Treatment Populations – Maintenance, Combination & Preventive Therapy
Alzstatin ® – gamma-secretase modulator Multiple Treatment Populations – Maintenance, Combination & Preventive Therapy Maintenance therapy - in patients with established Alzheimer’s disease • Treatment after initial plaque clearance by monoclonal antibody treatment (as initially proposed by Lilly) e
Slide 22: Early clinical Proof-of-Mechanism – Already in Phase I
Alzstatin ® – gamma-secretase modulator Early clinical Proof-of-Mechanism – Already in Phase I • Phase I will demonstrate proof of mechanism (PoM) and central target engagement • SAD/MAD studies conducted in healthy volunteers + Alzheimer’s patients • Evaluation of safety and tolerability after sing
Slide 23: Interim phase II data on a GSM by Roche expected in 2026
Alzstatin ® – gamma-secretase modulator Interim phase II data on a GSM by Roche expected in 2026 The data is validating & increasing interest in Alzstatin® 23
Slide 24: PainLess – targeting unmet medical needs within pain
PainLess – targeting unmet medical needs within pain
Slide 25: Introduction to our platforms PainLess
PainLess Introduction to our platforms PAINLESS Osteoarthritis & severe pain Neuropathic pain conditions > 300 million patients > 600 million patients Project: ACD137 Project: ACD440 Negative allosteric modulator of TrkA- Topical TRPV1 antagonist in clinical receptors in research phase Phase II 25
Slide 26: ACD137 – Non-Opioid Treatment of Osteoarthritis & Severe Pain
ACD137 - Negative allosteric modulator of TrkA-receptors ACD137 – Non-Opioid Treatment of Osteoarthritis & Severe Pain Attractive E.g., osteoarthritis in patients who have experienced insufficient pain relief from 1st line target population standard of care or unacceptable side effects Clinical Mech
Slide 27: ACD137 positions AlzeCure in next-generation TrkA pain therapies
ACD137 - Negative allosteric modulator of TrkA-receptors ACD137 positions AlzeCure in next-generation TrkA pain therapies Compound Company TrkA (nM) TrkB (nM) TrkA vs TrkB Status Indication OA1 & ACD137 AlzeCure 0.87 26 400 30,300 Preclin other pain conditions Cmpd #10 Array Bio. OA 0.038 210 5,500
Slide 28: ACD137 demonstrates anti-NGF–like efficacy with improved safety profile
ACD137 - Negative allosteric modulator of TrkA-receptors ACD137 demonstrates anti-NGF–like efficacy with improved safety profile TrkA-NAM ACD137 – Efficacy on par with NGF antibody • We have used the rat MIA model to assess the cartilage degeneration, localized inflammation, and pain behaviors after
Slide 29: ACD440 – Novel TRPV1 antagonist in clinical phase for neuropathic pain
ACD440 – a TRPV1 antagonist ACD440 – Novel TRPV1 antagonist in clinical phase for neuropathic pain Project overview Emanates from Big Pharma TRPV1 – Optimized for local delivery Positive clinical trial results in phase Ib & IIa • Approximately 20M USD already • The vanilloid receptor subtype 1 • Dev
Slide 30: Positive phase IIa results for First-in-Class ACD440
ACD440 – a TRPV1 antagonist Positive phase IIa results for First-in-Class ACD440 • Demonstrate Positive Proof-of-Mechanism (PoM) results in patients with chronic peripheral neuropathic pain in a placebo cross-over trial • The patients have had chronic pain for many years & were on concomitant medica
Slide 31: Positive regulatory support from the FDA
ACD440 – a TRPV1 antagonist Positive regulatory support from the FDA Erythromelalgia • Erythromelalgia is a rare chronic painful disorder – ”burning feet syndrome” existing in children & adults • Triad of redness, swelling and intense pain • Pain comes in attacks, flares, triggered by heat or exerci
Slide 32: Summary
Summary
Slide 33: Key Investment Highlights in AlzeCure
Key Investment Highlights in AlzeCure Targeting areas of significant unmet medical needs m Strong team with extensive experience and track record – from idea to clinic Platforms with first-in-class properties and potential game-changers Parallel investments in several candidates and potent follow-up
Slide 34: Appendix
Appendix
Slide 35: The AlzeCure management team
Management team The AlzeCure management team - Extensive experience from the industrial drug development value chain MANAGEMENT TEAM Märta Segerdahl Storck Pontus Forsell Cecilia Wadell Martin Jönsson Johan Sandin Birgitta Lundvik CMO Head of Discovery, Head of Development, CEO CSO, Ph.D. CFO M.D.,
Slide 36: Board of Directors
Board of Directors Board of Directors - Complementing expertise for the continuous development of AlzeCure BOAR D OF DIRECTOR S Thomas Pollare Jan Lundberg Eva Lilienberg Ragnar Linder Dr Janet Hoogstraate Chairman of the Board Director of the Board Director of the Board Director of the Board Direct
Slide 37: The AlzeCure scientific advisory
Scientific advisors The AlzeCure scientific advisory - Network of leading scientific advisors within neurodegenerative disorders SCIENTIFIC ADVISORS Professor Professor Professor Ass. Professor Doctor Professor Bengt Winblad Henrik Zetterberg Peter Snyder John Harrison Rolf Karlsten Sven Ove Ögren •
Slide 38: Financial status as per Q3 2025
Financial summary Financial status as per Q3 2025 P&L in brief Shareholder structure per December 23, 2025 Q3 2025 Q3 2024 Net sales 0 0 BWG Invest Sàrl (William Gunnarsson) 15.00% Research expenses -21,375 -18,196 Operating loss -30,014 -26,431 Peter Thelin (Seven Holding) 7.79% Earnings for the pe
Slide 39: Karolinska Institutet Novum Science Park
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN Martin.jonsson@alzecurepharma.com www.alzecurepharma.com